N@N

Teva Pharma, Zoetis, Orexigen Therapeutics, Novartis, and Actavis Early Briefing and Review

^{Published on 2013-03-05 05:15:35 - Market Wire}
 

Teva Pharma, Zoetis, Orexigen Therapeutics, Novartis, and Actavis Early Briefing and Review -- LONDON, March 5, 2013 /PRNewswire/ --

LONDON, March 5, 2013 /PRNewswire/ --

The Healthcare sector showed a healthy trend as the markets continued their upward ascent. Major drug manufacturing remained range-bound with positive bias as the sector prepares to deal with healthcare regulations. On Monday, The Dow Jones ended its latest session at 14,127.82, up 0.27 percent while NASDAQ was up 0.39 percent to close at 3,182.03. Similarly, S&P also ended at a positive note at 1,525.20, up 0.46 percent. Our research team took a look at Healthcare sector, notably the Drug Manufacturers  industry which includes major companies like Teva Pharmaceutical Industries Ltd (NYSE: [ TEVA ]), Zoetis Inc. (NYSE: [ ZTS ]), Orexigen Therapeutics Inc. (NASDAQ: [ OREX ]), Novartis AG (NYSE: [ NVS ]) and Actavis Inc. (NYSE: ACT). StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at

[ http://www.stockcall.com/report ] 

Teva Pharmaceutical Industries Ltd traded in the range of $37.03 and $37.44 in its latest trading session and ended the day flat at $37.25. The stock's 52 weeks range stands at $36.63 and $46.38. Teva has lost 17.68 percent of its value in the past 12 months, while it lost 0.24 percent so far this year so far. Teva Pharmaceutical Industries Ltd is in a neutral mode and may find its first support level at $37.11. It is trading below its 20-day moving average of $38.05. Sign up for the free report on TEVA at

[ http://www.StockCall.com/TEVA030513.pdf ] 

Shares of Zoetis Inc. ended Monday's trading session marginally down at $34.35, 0.72 percent. The stock gained more than 10 percent this year, outperforming the broad market. It has support at around $33.54 at the moment. Despite its downward movement, the company is still trading above its 50-day moving average price of $33.64. The stock traded 865,000 shares during the session. ZTS free technical report can be accessed by signing up at

[ http://www.StockCall.com/ZTS030513.pdf ] 

Orexigen Therapeutics stock is in a bullish mode and is trading above its 20-day SMA of 6.44. It ended its latest trading session 7.28 percent higher at $6.48, and the stock oscillated in the range of $5.92 and $6.49 during Monday's session. The stock trades at beta of 1.94. Orexigen is expected to face its first resistance level at $6.63. Free report on OREX can be accessed by registering at

[ http://www.StockCall.com/OREX030513.pdf ] 

Novartis AG stock closed at $68.90, 1.10 percent up. The stock traded in the range of $68.33 and $68.91 during the session and is currently above it 20-day moving average price of $68.83. The drug maker gained 8.85 percent so far this year. Its Price/Earnings ratio is 17.71. Novartis stock is in a bullish phase and its first resistance level is at $70.14. On the downside, its first support is at $67.87. Upon breaching this level, its second support level is at $66.58. Register with StockCall and download the research on NVS for free at

[ http://www.StockCall.com/NVS030513.pdf ] 

With a mild upward movement in yesterday's trading session, Actavis Inc. is up 0.23 percent for the year. It has gained 44.44 percent in the past 52 weeks. The stock closed 0.77 percent higher at $86.20 on volume of 817,000 shares. Its average trading volume stands at 1.27 million shares. The company's shares currently face resistance at around $87.88. The stock has support at around $83.90. It is currently trading above its 20-day and 50-day moving averages, which is a bullish signal. Read the full free research on ACT by signing up to StockCall at

[ http://www.StockCall.com/ACT030513.pdf ] 

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

[ http://www.stockcall.com ] 

SOURCE StockCall.com